Benefits
Bone-Identical Mineral Form
Hydroxyapatite (Ca10(PO4)6(OH)2) is the actual mineral structure of human bone and tooth enamel. MCHA provides calcium and phosphorus in the same crystalline form found in bone — proposed advantage for bone matrix incorporation.
Postmenopausal Bone Density (Some Evidence)
Several trials suggest MCHA produces equal-or-better BMD effects vs calcium carbonate or citrate in postmenopausal women. Castelo-Branco et al. trials and Pelayo et al. 2007 four-year follow-up support efficacy. Not consistently superior in head-to-head comparisons.
Phosphorus Content
MCHA provides phosphorus alongside calcium — bone needs both. Most calcium supplements lack phosphorus; MCHA's phosphorus content matches bone composition.
Organic Matrix Components
MCHA contains residual collagen-derived peptides, growth factors (theoretically), and trace elements from bone matrix — distinct from simple inorganic calcium salts.
Slow Calcium Release
Hydroxyapatite has lower acute solubility than calcium carbonate or citrate — leads to smaller transient calcium spikes. Some practitioners propose this is more physiological.
Mechanism of action
Hydroxyapatite Crystal Structure
Calcium phosphate crystallized as Ca10(PO4)6(OH)2 — the identical mineral structure of bone hydroxyapatite. Slowly dissolves in stomach to release Ca²⁺ and phosphate ions for absorption.
Phosphorus + Calcium Combined
Bone is ~99% hydroxyapatite (calcium phosphate) — providing both minerals together is theoretically more physiologic than calcium-only supplementation.
Slower Absorption
Lower acute solubility means slower calcium release vs carbonate/citrate — smaller serum calcium spikes; some practitioners consider this safer for cardiovascular concerns about calcium supplementation.
Bovine Bone Source Variability
MCHA quality varies significantly by source — bovine origin (concerns about BSE/prion contamination, pesticide exposure, antibiotic residues), processing methodology, and standardization. New Zealand-sourced MCHA is generally considered higher-quality.
Clinical trials
RCT comparing acute and 3-month effects of MCHA, calcium citrate, and calcium carbonate on serum calcium and bone turnover markers in postmenopausal women.
Postmenopausal women.
MCHA produced smaller serum calcium AUC vs citrate/carbonate (slower absorption) but similar effect on bone turnover markers. PTH suppression less pronounced with MCHA — interpreted as more physiological pattern. Not directly superior on hard outcomes.
Four-year follow-up of OHC supplementation for osteoporosis prevention in postmenopausal women.
Postmenopausal women.
MCHA/OHC supported BMD maintenance over 4 years. Industry-funded research; not direct comparison to bisphosphonates (which are gold-standard pharmacotherapy for osteoporosis).
About this ingredient
Microcrystalline hydroxyapatite (MCHA, also called ossein-hydroxyapatite complex / OHC) is calcium derived from BOVINE BONE — providing calcium PLUS phosphorus PLUS collagen-derived organic matrix in the same hydroxyapatite crystal structure found in human bone. Chemical formula: Ca10(PO4)6(OH)2 with associated organic matrix. Elemental calcium content: ~24% by weight; also provides ~12% phosphorus.
CRITICAL DISTINCTION FROM SIMPLE CALCIUM SALTS: MCHA is whole bone-derived, not synthesized calcium phosphate — contains residual organic matrix components (collagen-derived peptides, trace elements, growth factor remnants). EVIDENCE BASE: several RCTs (Castelo-Branco 2014, Pelayo 2007 OHC follow-up) support MCHA for postmenopausal bone health; not consistently superior to citrate/carbonate in head-to-head comparisons.
EVIDENCE-BASED USES: (1) Postmenopausal bone health adjunct; (2) Calcium + phosphorus combined supplementation; (3) Premium calcium supplementation for those preferring 'whole-food' calcium source; (4) Patients seeking lower acute serum calcium spikes vs ionic forms.
CRITICAL CAUTIONS: (1) BOVINE SOURCE — BSE/prion concerns historically; reputable manufacturers source from BSE-free regions (New Zealand, Argentina) and verify; AVOID if BSE source unclear; (2) NOT vegetarian/vegan; may not be kosher/halal depending on source; (3) PESTICIDE/ANTIBIOTIC residues — animal sourcing may carry contaminants; verify third-party testing; (4) PHOSPHORUS CONTENT — CKD patients on phosphorus-restricted diets must AVOID MCHA; phosphate binders are core CKD nutrition; (5) DOSE — calcium absorption still maxes at ~500 mg single dose; divide; UL 2,500 mg/day total calcium; (6) DRUG INTERACTIONS — same as other calcium forms; (7) HYPERCALCEMIA at chronic very high doses; (8) COST — substantially more expensive than carbonate/citrate; cost-benefit favors MCHA for those specifically wanting whole-bone-source calcium with phosphorus; (9) KIDNEY STONES — phosphorus content is theoretically RELEVANT for stone-formers; consult urology; (10) PREGNANCY/LACTATION — generally safe with reputable sourcing; (11) For evidence-based osteoporosis treatment, BISPHOSPHONATES (alendronate, risedronate, zoledronate), DENOSUMAB, TERIPARATIDE remain pharmaceutical gold standard; calcium + vitamin D supplementation adjunctive.